Strategic Collaboration Between Nanjing GenScript Biotech and Merck to Advance Cell and Gene Therapy Manufacturing
MSD
Pharmaceutical R&D and Manufacturer
Nanjing GenScript Biotech, a globally leading contract development and manufacturing organization (CDMO) in the biopharmaceutical industry, and Merck, a globally leading technology company, today jointly announced their first-ever comprehensive strategic collaboration in the field of cell and gene therapy, to jointly promote cellular immunity andGene TherapyThe industrialization process of the industry.
Signing Ceremony Photos
Under the agreement, Merck will provide GenScript with comprehensive 360-degree services in plasmid and viral vector production, covering products and process technologies, facility design consultation, quality system establishment, GMP compliance consulting, and personnel training, to support GenScript’s plasmid and viralCarrierDevelopment of a Production Service Platform and Internationalization Strategy. The two companies will engage in comprehensive cooperation in the areas of plasmid and viral vector quality systems and GMP compliance, process and facility design, and market promotion.
As a CDMO that previously supported Nanjing Legend in completing its clinical trial application filings in the field of cell therapy, GenScript boasts GMP-compliant manufacturing facilities designed and constructed in accordance with cGMP requirements in the United States, Europe, and China, along with a mature process development and quality research platform. The strategic agreement signed between GenScript and Merck aims to comprehensively integrate internal resources to maximize customer benefits, fostering mutual growth and win-win outcomes through long-term strategic collaboration between the two companies.
Group Photo of All Attendees
"Today, global cell and gene therapy is developing rapidly; meanwhile, the commercialization of cell and gene therapy faces numerous challenges." At the signing ceremony, Mr. Wang Dongliang, Vice President of Operations for GenScript Biologics Division, first addressed the entire cellGene Therapyan analysis of the current state of the field and market trends, stating, “We are delighted to enter into a strategic collaboration with Merck. Leveraging the exceptional cGMP manufacturing facilities created through this powerful partnership, we will better serve both domestic and international customers, thereby fulfilling our mission to help clients accelerate their commercialization processes.”
Address by Mr. Wang Dongliang, Vice President of Operations, Biologics Business Unit, GenScript
“Production of High-Quality Plasmids and VirusesCarrieris cellular andGene Therapy"a key step in the commercialization process," said Udit Batra, Member of the Executive Board of Merck and CEO of Life Science, "Merck is the world's largest virusCarrier“As one of the manufacturers, this collaboration will enable GenScript to leverage our nearly 30 years of experience in gene and cell therapy production.” Ms. Wang Muyang, General Manager of Merck Life Science Process Solutions China, and Mr. Benoit Opsomer, Vice President of Merck Life Science Bioprocessing and Head of Asia Pacific, attended the signing ceremony and delivered remarks.
Vice President, Bioprocessing, Merck Life Science & Head of Asia Pacific
Address by Mr. Benoit Opsomer
Address by Ms. Wang Muyang, General Manager of Merck Life Science Process Solutions China
This strategic cooperation has attracted widespread attention. Following the signing ceremony, Mr. Wang Dongliang, Vice President of Operations for GenScript’s Biologics Division; Wei Shigang, Deputy Director of Plasmid and Viral Process Development; and Benoit, Vice President of Merck Life Science’s Bioprocess Business and Head of the Asia-Pacific Region,Benoit OpsomerMr. [Name] and Ms. Wang Muyang, General Manager of Merck Life Science Process Solutions China, were interviewed by three media outlets, including Yicai Daily, MedPeer, and PharmaCube. The detailed interview content will be released subsequently.About GenScript Biotech
GenScript is a leading biopharmaceutical contract development and manufacturing organization (CDMO) in China, featuring custom biological reagent platforms for gene synthesis, peptide synthesis, antibody development, and protein expression, as well as a one-stop platform for biologic drug research and development. GenScript offers comprehensive one-stop solutions for antibody drug development, covering antibody discovery services such as hybridoma technology, phage display technology, fully human antibody technology, and bispecific antibody technology, along with antibody engineering services including humanization, developability assessment and optimization, and affinity maturation. GenScript’s integrated cell therapy solutions encompass IND application dossier preparation, clinical sample production, and commercial-scale manufacturing.Production ProcessDevelopment controls ensure compliance, authentic and complete records guarantee traceability, and all trial deviations are rigorously investigated and documented. GenScript consistently adheres to the philosophy of “delivering the highest quality to customers and serving their best interests,” committed to helping clients shorten the timeline for bringing innovative biologics into clinical trials, significantly reducing R&D costs, accelerating medical translation, building a healthier future together, and supporting the “Made in China” initiative in the pharmaceutical industry by 2025.
About Merck
Merck is a leading science and technology company focused on three core areas: Healthcare, Life Science, and Performance Materials. Approximately 52,000 employees worldwide work at Merck to drive technological progress and improve people’s lives, with offerings ranging from biopharmaceutical therapies for cancer and multiple sclerosis, to cutting-edge systems for scientific research and production, to liquid crystal materials for smartphones and flat-screen TVs. In 2018, Merck generated total sales of €14.8 billion across 66 countries.
Merck is the world’s oldest pharmaceutical and chemical company. As the founders, the Merck family still holds the majority of the company’s shares, and Merck is one of the 30 largest German companies listed on the Frankfurt Stock Exchange. Headquartered in Darmstadt, Germany, Merck owns the global rights to the “Merck” name and brand, with the sole exceptions being Canada and the United States, where the company operates under the names EMD Serono, MilliporeSigma, and EMD Performance Materials.